The Ross procedure has received increasing interest as an attractive alternative to a prosthetic aortic valve. Given its presumably greater resistance to infection, the pulmonary autograft is theoretically preferable for active endocarditis. The objective of this retrospective study was to present our experience in aortic valve endocarditis treated using the Ross procedure.
INTRODUCTION
Controversy exists regarding which valve type is best for the management of aortic endocarditis. Despite advances in antimicrobial therapy and surgical management, morbidity and mortality remain high, particularly in prosthetic valve endocarditis [1] and paravalvular abscess [2] . One of the difficulties faced by the surgeon is selecting the optimal substitute for the infected aortic valve. A prosthetic valve implantation in an infectious context is never satisfactory. In addition, implantation of a bioprosthesis in young patients exposes them to the risk of early degeneration and multiple reoperations. Furthermore, the anticoagulation associated with mechanical valves may be inappropriate in patients with severe social disruption or comorbidities. The aortic homograft and the pulmonary autograft have several theoretical advantages: their tissue can bridge any potential defects related to the debridement of infected tissue, they have good resistance to infection and excellent haemodynamic performance, particularly in small aortic ring sizes, and they do not require anticoagulation. Pulmonary autografts seem to have better durability than homografts [3] ; however, the Ross procedure is a more complicated surgical approach and involves double-valve replacement. To evaluate the theoretical advantages of autografts, in particular, in recurrent endocarditis, we reviewed our 15 years of experience in aortic valve endocarditis treated using the Ross procedure.
METHODS
The Ethics Committee approved this retrospective study and waived the need to obtain patient consent for the study.
according to the Duke criteria [4] . Endocarditis affected the native aortic valve in 24 patients, a biological prosthetic valve in 3 and a mechanical prosthetic valve in 1. Two of the redo bioprosthesis patients were initially operated on for endocarditis. Two others prosthetic valve endocarditis cases were primary. The patients ranged in age from 19 to 57 years (mean age, 42; standard deviation [ ± ] 8.4 years). The mean body surface area of the patients was 1.8 ± 0.2 m 2 . Table 1 summarizes the major comorbidities of the 28 patients treated using the Ross procedure. Preoperative standard EuroSCORE was 8.1 ± 4.0 (range [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] in 28 endocarditis patients. Thirteen of the 28 patients underwent surgery during the acute phase of endocarditis in response to an emergency. Fourteen patients underwent emergency surgery (vegetation threatening for 5 patients, intracardiac conduction disturbance for 1 and massive aortic insufficiency with signs of ventricular failure for 7). One patient whose antibiotic therapy was completed while waiting for elective Ross surgery eventually received emergency surgery for cardiac decompensation of his aortic insufficiency.
Preoperative evaluation
Nine patients were in New York Heart Association (NYHA) class I, 9 patients were in Class II, 7 patients were in Class III and 3 patients were in class IV. The preoperative left ventricular systolic function (LVEF) expressed as ejection fraction was 61.3 ± 10.1% (range, 40-77%) and the left ventricle end-diastolic diameter was 60 ± 7.5 mm (range, 42-73 mm). Table 2 shows the isolated causative organism.
Surgical technique
Cardiopulmonary bypass was conducted in moderate hypothermia (32.4°C) in all patients. Continuous warm blood retrograde cardioplegia was used until July 2010 (23 patients), after which crystalloid anterograde cardioplegia (Custodiol ® , Eusapharma, Limonest, France) was used (5 patients). The pulmonary autograft was implanted in all patients in the aortic position using the root technique, combined with a wide strip of equine pericardium incorporated into the annulus suture line to stabilize or prevent annulus dilatation. From September 2010, our surgical technique has evolved through autograft inclusion in polyester tube prosthesis to prevent dilatation of the pulmonary autograft. To avoid any artificial material, we have not proposed this technique to these 28 endocarditis Ross patients. The right ventricle outflow was reconstructed using a cryopreserved homograft in 25 patients. The mean diameter of the homograft was 25.4 ± 1.8 mm (range, 23-31 mm). The right ventricle outflow was restored using a stentless valve (Prima ® , Edwards Lifescience, Irvine, California, USA) in 3 patients due to limited homograft availability. A concomitant procedure was performed in 4 patients (mitral valve repair, pericardial decortication, sus-coronary prosthetic tube and resection of subvalvular membrane). The crossclamp time ranged from 97 to 218 min (mean, 137 ± 31 min) and the cardiopulmonary bypass time from 118 to 324 min (mean, 174 ± 45 min).
Operative findings
An annular abscess consisting of two aorticomitral junction abscesses, a septum abscess and an abscess in the fibrous trigone were observed in 8 patients. Cusp perforations or destructions were observed in 16 patients, and 12 had aortic valve infective vegetations. 
Follow-up

Statistical analysis
Values are expressed as the mean ± standard deviation unless otherwise indicated. Actuarial estimates of overall survival and freedom from autograft reoperation were accomplished with Kaplan-Meier methods. Statistical analyses were performed using the statistical software Winstat 2009.1 ® , (R. Fith Software, Bad Krozingen, Deutschland). 
RESULTS
The mean follow-up was 6.4 ± 4.2 years (range, 0.5-12.9 years).
Mortality and hospital morbidity
Hospital mortality was 10.7% (3 patients). One patient died on day 2 in cardiogenic refractory shock after cardiac arrest. The other 2 patients died of non-cardiac causes. One patient died of a haemorrhagic stroke on day 3, suggesting a possible mycotic cerebral aneurysm rupture. One patient died on day 7 of haemorrhagic complications due to a transfixing chest tube through the ascending aorta after implantation for pneumothorax.
The mean duration of mechanical ventilation was 1.6 ± 3.3 days (range, 0-16 days). The duration of ICU stay was 4.3 ± 3.7 days (range, 1-18 days). The mean length of hospital stay of the survival patients was 13.8 ± 11 days (range, 6-58 days).
Postoperative echocardiographic evaluation at discharge LVEF was 59 ± 7% (range: 49-69%). The mean gradient of the autograft was 4.4 ± 3.2 mmHg (range: 2-14 mmHg). The mean gradient of the right outflow tract was 6 ± 4.6 mmHg (range: 2-19 mmHg). All patients had an aortic insufficiency less than grade 1.
Late mortality
Six patients died during follow-up. All patients died of extracardiac causes. Table 3 reports the causes of late death. Figure 1 shows overall patient survival. Actuarial survival at 10 years free of cardiac death was 96 ± 3.5%.
Reoperation
Four patients underwent further surgery after hospital discharge. Two of these four reoperations were required due to recurrent endocarditis. One patient was treated for aortic regurgitation due to aortic ring dilatation. One patient underwent surgery on the right and left ventricular outflow tract following new endocarditis due to a different germ. One patient required mitral valve replacement 10 years after mitral valve repair. One patient required mitral valve repair due to recurrent endocarditis 2 years after the Ross procedure. Actuarial freedom from any cardiac reoperation and the Ross reoperation was 67 ± 15.1 and 85.2 ± 9.8% 
Clinical follow-up
At the last investigation, 18 of 19 surviving patients were in NYHA Class I. One patient was in Class II.
Late echocardiographic evaluation Table 4 shows the echocardiographic data from surviving patients.
DISCUSSION
The best aortic valve substitute to use in infective endocarditis
has not yet been established, and clinical practice guidelines, even in the presence of a periannular abscess, have not been precisely determined [5] . A bioprosthesis exposes young patients to the risk of early degeneration and multiple reoperations. Moon and coworkers reported 19.6% freedom from reoperation at 15 years for patients <60 years of age who underwent surgery on biological valves for endocarditis [6] . In patients under 65 years, Nguyen et al. [7] reported a 4-fold higher 5-year mortality risk in patients treated for endocarditis with a bioprosthesis vs a mechanical prosthesis. However, the authors did not necessarily attribute this excess mortality to early degeneration of the valve.
Comorbidities presented by subjects with infective endocarditis (alcoholism, drug addiction, social disruption) are often absolute contraindications to the anticoagulant therapy associated with mechanical valves. In addition, the implantation of a biological or mechanical prosthetic valve in the septic context remains unsatisfactory.
Large defects after debridement of infected tissue can be difficult to repair with a simple valve prosthesis, explaining why, for many surgical teams, the homograft remains the substitute of choice as an alternative to prosthetic material [8] . However, homografts have a limited life span, and wall calcification may complicate future surgery. Vogt et al. [9] reported the use of homografts in a series of 49 patients who underwent emergency surgery for endocarditis. Hospital mortality was 8.2%. The 5-year survival free of reoperation was 69 ± 9%, with morbidity related mainly to homograft degeneration. However, other studies found no differences after 10-year follow-up in terms of recurrence of endocarditis, reoperation or survival between homografts and prosthetic valves [1, 10] . One patient had no data.
The Ross procedure has many theoretical advantages in endocarditis aortic valve surgery: autologous tissue provides resistance to infection, anticoagulation is not required, and it has better durability in comparison with homografts [3] . The defect created by the infected tissue resection can be patched using an autograft. Finally, endocarditis represents a small percentage of patients in the different published series involving the Ross procedure: 8% in the series of Elkins et al. [11] , 7.5% in the series of Kouchoukos et al. [12] , 5% of 501 patients in the series of Sievers et al. [13] and 1 patient of 155 published by Paparella et al. [14] . Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database reveals that from 2002 to 2008, of the 4866 surgeries for aortic endocarditis, only 5 patients underwent a Ross procedure, whereas 31.8% received mechanical AVR, 60.7% a biological AVR, 5.3% a homograft, 2% had missing data and 0.2% had an aortic valvuloplasty (11 patients) [15] . Few series specifically report the results of the Ross procedure in endocarditis. Prat et al. [16] reported 11 patients receiving surgery during the acute phase of endocarditis. The authors reported no deaths or recurrent endocarditis. Pettersson et al. [17] , in 1998, published the results of 35 endocarditis patients treated using the Ross procedure. They reported two hospital deaths and no deaths during the mean 2-years follow-up. In this series, one recurrence of endocarditis was noted. Schmidtke et al. [18] reported a series of 20 patients operated on for endocarditis. They reported no recurrence of endocarditis after a mean follow-up of 3.8 years. Joyce et al. [19] reported 11 patients who underwent a Ross procedure without complication after a mean follow-up of 8 months. Niwaya et al. [20] reported a series of 81 patients treated for endocarditis, including 25 Ross procedures. The authors favoured the Ross procedure for patients whose life expectancy was over 20 years. They reported a 5-year survival of 88%. Stelzer et al. [21] reported less-encouraging results for the 11 endocarditis cases in their series of 145 Ross procedures, with 66% having serious complications (death for 3 patients, 3 with recurrence of endocarditis and 2 patients who required further surgery on the autograft).
The actuarial survival of our 28 patients, including the three operative deaths, was low, at 47 ± 13% at 10 years, but comparable to published data. David et al. [2] reported on a large series of 383 patients operated on for endocarditis, with a survival of 44% at 15 years. Moon et al. [6] reported on 306 patients with a 10-year actuarial survival of 50 and 51% for bioprostheses and mechanical valves, respectively. The severity of symptoms and their heavy comorbidities explain these results.
During a mean follow-up of 6.4 ± 4.2 years, we observed three recurrences of endocarditis, and an actuarial survival free of recurrent endocarditis at 12 years, of 84.4 ± 8.4%. Of the 3 patients with recurrent endocarditis, 1 had mitral endocarditis sparing the autograft and 1, who had not stopped his intravenous drug use, presented homograft endocarditis with a different germ from the first episode. These 2 patients, strictly speaking, should not be considered as cases of recurrent endocarditis. These results illustrate the qualities of resistance to infection of the pulmonary autograft, and are similar to those of published series in which endocarditis was treated with an aortic prosthesis. In a study of 122 patients treated during the acute phase of infective endocarditis, of whom 119 received a prosthetic valve, D'Udekem et al. [22] reported 79% freedom from recurrent prosthetic valve endocarditis at 10 years. Fedoruk et al. [23] reported on 357 patients who received a prosthetic valve, with 78.9 ± 4.4% of freedom from recurrent prosthetic valve endocarditis at 15 years. This series did not include patients who underwent surgery in the acute phase.
Limitations
This was an observational study, and in the absence of control subjects, we cannot provide evidence of the superiority of the Ross procedure.
CONCLUSION
The choice of which type of aortic valve replacement to make in endocarditis in young patients is difficult. The pulmonary autograft is an alternative to prosthetic valves, with a low rate of reoperation and recurrent endocarditis. The relative difficulty of the intervention means that centres that already have extensive experience of this procedure should use this technique as part of the treatment protocol for endocarditis.
